 |
1 Product |  |
0 Diseases | | 1 Product |
|
1 Trial |  |
3 News |  |
- conteltinib (SY-707) / Centaurus Biopharma, Shouyao Holdings, SY-5933 / Shouyao Holdings
Targeting FAK to improve the therapy of KRAS G12C mutant cancers (Section 24) - Mar 5, 2024 - Abstract #AACR2024AACR_4014;
In conclusion, our results demonstrate that CT-707 has the potential to enhance the efficacy of SY-5933 by suppressing adaptive FAK activation under KRAS G12C inhibition. This provides a rationale for an innovative combination therapy to improve outcomes in patients with KRAS G12C mutated cancers.
- || Review, Journal: Roles and inhibitors of FAK in cancer: current advances and future directions. (Pubmed Central) - Feb 27, 2024
This review aims to clarify FAK's role in cancer, offering a comprehensive overview of the current status and future prospects of FAK-targeted therapy and combination approaches. The goal is to provide valuable insights for advancing anti-cancer treatment strategies.
- || conteltinib (SY-707) / Centaurus Biopharma, Shouyao Holdings
P1 data, Journal: Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study. (Pubmed Central) - Nov 25, 2022
P1
In this study, conteltinib showed manageable safety profile, favorable PK properties, and anti-tumor activity in advanced ALK-positive NSCLC patients. The recommended phase 2 dose was determined to be 600 mg QD for ALK TKI-naïve patients and 300 mg bis in die (BID) for patients who received crizotinib previously.
- | conteltinib (SY-707) / Centaurus Biopharma, Shouyao Holdings, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
New P1/2 trial, Combination therapy, Metastases: Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer (clinicaltrials.gov) - Oct 14, 2022
P1/2, N=114, Recruiting, Sponsor: Shouyao Holdings (Beijing) Co. LTD
- CT-1530 / Centaurus Biopharma
Hybrid erbium(III)–bacteriochlorin near-infrared probes for multiplexed biomedical imaging (Virtual-only (Zoom)) - Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_6362;
(g) Preparation of the CT1530 and through-skull intravital microscopic imaging of cancer metastasis. (h) Schematic illustration showing the protocol of NIR-II intravital microscopic imaging (i) Dual pseudo-color images of the cancer cells (red) and the blood vessels (green), performed by using emission-multiplexed method.
- | conteltinib (CT-707) / Centaurus Biopharma, Nexavar (sorafenib) / Bayer, Amgen
Journal: CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling. (Pubmed Central) - Apr 27, 2022
(h) Schematic illustration showing the protocol of NIR-II intravital microscopic imaging (i) Dual pseudo-color images of the cancer cells (red) and the blood vessels (green), performed by using emission-multiplexed method. Overall, this study not only favors the development of this novel multi-kinase inhibitor CT-707 as a therapeutic agent against HCC, but also provides a potential strategy to overcome the hypoxia-mediated resistance to sorafenib in HCC patients.
- || TQ-F3083 / Centaurus Biopharma
Clinical, P1 data, Journal: First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults. (Pubmed Central) - Aug 10, 2021
The concentration of active glucagon-like peptide-1 increased after TQ-F3083 administration, but no obvious dose dependency was observed. TQ-F3083 was well tolerated in healthy Chinese adults, and the pharmacokinetic and pharmacodynamic characteristics support further evaluation of TQ-F3083 in a trial in T2DM patients.
- || conteltinib (CT-707) / Centaurus Biopharma
Clinical, Journal: Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. (Pubmed Central) - Mar 16, 2021
This study indicated that CT-707 is clinically effective as a new antitumor drug for Chinese lung adenocarcinoma patients with ALK rearrangement. It is safe and reliable and the dose-expansion phase recruitment has started.
- | Xalkori (crizotinib) / Pfizer, conteltinib (CT-707) / Centaurus Biopharma
Journal: CT-707 Overcomes Resistance of crizotinib through activating PDPK1-AKT1 pathway by targeting FAK. (Pubmed Central) - Sep 23, 2020
It is safe and reliable and the dose-expansion phase recruitment has started. These findings indicate that CT-707 may be a promising therapeutic agent against crizotinib-resistance in NSCLC.
- ||| TQ-F3083 / Centaurus Biopharma
Enrollment open, Trial initiation date: Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Mar 13, 2020
P2a, N=120, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
These findings indicate that CT-707 may be a promising therapeutic agent against crizotinib-resistance in NSCLC. Not yet recruiting --> Recruiting | Initiation date: Jul 2019 --> Jan 2020
- |||| TQ-F3083 / Centaurus Biopharma
New P2a trial: Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jun 13, 2019
P2a, N=120, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- |||| CT-1530 / Centaurus Biopharma
Enrollment open: Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Jul 19, 2017
P1/2, N=200, Recruiting, Sponsor: Centaurus Biopharma Co., Ltd.
Not yet recruiting --> Recruiting | Initiation date: Jul 2019 --> Jan 2020 Not yet recruiting --> Recruiting
- ||| CT-1530 / Centaurus Biopharma
Trial initiation date: Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Mar 10, 2017
P1/2, N=200, Not yet recruiting, Sponsor: Centaurus Biopharma Co., Ltd.
Not yet recruiting --> Recruiting Initiation date: Dec 2016 --> Apr 2017
- conteltinib (SY-707) / Centaurus Biopharma, Shouyao Holdings
Enrollment open: Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Feb 2, 2017
P1, N=40, Recruiting, Sponsor: Centaurus Biopharma Co., Ltd.
Initiation date: Dec 2016 --> Apr 2017 Not yet recruiting --> Recruiting
- ||||| CT-1530 / Centaurus Biopharma
New P1/2 trial: Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Dec 4, 2016
P1/2, N=200, Not yet recruiting, Sponsor: Centaurus Biopharma Co., Ltd.
- conteltinib (SY-707) / Centaurus Biopharma, Shouyao Holdings
New P1 trial: Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 1, 2016
P1, N=40, Not yet recruiting, Sponsor: Centaurus Biopharma Co., Ltd.